NRX PHARMACEUTICALS, INC. — Income Charts
33 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$983K
Cost of Revenue
$408K
R&D↓-46.1% -$478K
$558K
SG&A↑+75.9% +$2M
$5M
D&A↑+4100.0% +$41K
$42K
Operating Income↓-33.2% -$1M
$-4M
EBITDA↑+4100.0% +$41K
$42K
Interest Expense
$671K
Interest Income↑+0.0% +$0
$4K
Other Income/Expense
$-17M
Pretax Income↓-617.8% -$32M
$-37M
Tax Provision
$0
Net Income↓-262.9% -$4M
$-6M
Operating Margin
-1662.8%
Net Margin
-2433.9%
Effective Tax Rate↓-0.8pts
0.0%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-4.9pts
-0.2%
ETR Foreign Differential (pp)↑+0.3pts
0.3%
Operating Lease Cost
$91K
Revenue YoY Variation↓-29.5pts
-99.9%
Income YoY Variation↓-81.1pts
-33.2%
Revenue QoQ Variation
306.2%
Income QoQ Variation↓-65.0pts
-7.9%